Actively Recruiting
Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma
Led by City of Hope Medical Center · Updated on 2026-01-05
32
Participants Needed
1
Research Sites
166 weeks
Total Duration
On this page
Sponsors
C
City of Hope Medical Center
Lead Sponsor
N
National Cancer Institute (NCI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This phase II trial tests the safety of positron emission tomography (PET) guided stereotactic body radiation therapy (SBRT) and how well it works to treat non-small cell lung cancer (NSCLC), melanoma, and renal cell carcinoma (RCC) that has up to 5 sites of progression (oligoprogression) compared to standard SBRT. SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. A PET scan is an imaging test that looks at your tissues and organs using a small amount of a radioactive substance. It also checks for cancer and may help find cancer remaining in areas already treated. Using a PET scan for SBRT planning may help increase the dose of radiation given to the most resistant part of the cancer in patients with oligoprogressive NSCLC, melanoma, and RCC.
CONDITIONS
Official Title
Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed informed consent and assent when appropriate
- Agreement to allow use of archival tumor tissue or obtain approval if unavailable
- Age 18 years or older
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
- Diagnosed NSCLC with 1-5 sites of progression after at least 3 months of systemic checkpoint inhibitor therapy with or without chemotherapy
- Lesions amenable to SBRT and at least 1 cm in size
- Controlled primary tumor for more than 3 months in metachronous cases or treated with curative intent if synchronous progression
- At least one lesion with planned radiation dose biologic effective dose (BED) less than 100 due to organ risk
- Patients who may undergo other local therapies after discussion but must have at least one lesion treated with SBRT
- Treated brain metastases allowed, not counted as oligoprogression
- Life expectancy of 3 months or more as judged by investigators
You will not qualify if you...
- Investigator judgment that patient is unsuitable or unlikely to comply with study procedures
- Not eligible for SBRT after radiation oncologist review
- Unable to undergo PET/CT or no PET active disease
- Pregnant or breastfeeding women
- Female patients of childbearing potential must have negative pregnancy test within 72 hours prior to therapy
- Inability to comply with all study procedures due to feasibility or logistics
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
City of Hope Medical Center
Duarte, California, United States, 91010
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here